Omalizumab for Severe Asthma: Beyond Allergic Asthma
نویسندگان
چکیده
منابع مشابه
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
BACKGROUND Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician's global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also, there are no established criteria for identifying patients who will respond to omalizumab based on pre-tr...
متن کاملOmalizumab for the treatment of severe persistent allergic asthma.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of omalizumab for the treatment of chronic severe persistent allergic asthma, in accordance with the licensed indication, based upon the evidence submission from Novartis to the National Institute for Health and Clinical Excellence (NICE) as part of the single technolog...
متن کاملOmalizumab for severe allergic asthma: 7 years and open questions.
Anti-IgE treatment for severe allergic asthma has been available for more than seven years now. This treatment has clear clinical benefits and a good safety record. However, important questions concerning long-term dosing and treatment duration remain unanswered. This paper discusses the available information concerning the long-term use of omalizumab.
متن کاملOmalizumab for severe allergic asthma: a life changing drug?
Background Asthma is an airway condition and is associated with significant morbidity and mortality. The recent updates for treatment of asthma recommends omalizumab for use as add-on therapy in adults and children >6 years of age with inadequately controlled severe persistent allergic asthma. Omalizumab, a humanized anti-IgE mAb, specifically binds free IgE. The clinical efficacy of omalizumab...
متن کاملOmalizumab decreases IgE production in patients with severe allergic asthma
printing supported by . Visit Chiesi at Stand B2.10 MONDAY, SEPTEMBER 3RD 2012 cates that age and sex are the major risk factors. Detailed physiological mechanisms of the changing sex ratio are not fully known. We investigated the influence of gender in anti-IgE treated asthmatics. Methods: We pooled data from ten published studies from 1999 with more of our data of severe persistent asthmatics...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BioMed Research International
سال: 2018
ISSN: 2314-6133,2314-6141
DOI: 10.1155/2018/3254094